Beta-adrenergic and Alpha-1-adrenergic receptors (Beta-AR and Alpha-1-AR) (Beta-AR/Alpha-1-AR)

Adrenergic receptors are a class of G protein-coupled receptors (GPCRs) that mediate the physiological responses to the catecholamines epinephrine and norepinephrine within the sympathetic nervous system [StatPearls: Adrenergic Receptors]. This specific grouping encompasses the Alpha-1 (α1) and Beta (β) receptor subtypes, which are pivotal in regulating cardiovascular, respiratory, and metabolic functions. Alpha-1 receptors (α1A, α1B, α1D) are primarily located on vascular smooth muscle and mediate vasoconstriction through the Gq signaling pathway [PubMed: PMC4462033]. Beta receptors (β1, β2, β3) primarily couple to Gs proteins to increase intracellular cAMP; β1 receptors increase heart rate and contractility, while β2 receptors promote bronchodilation and vasodilation [UniProt: P08588, P07550]. Pharmacological agents that target both receptor types, such as the non-selective blockers carvedilol and labetalol, are used to treat hypertension and heart failure by combining peripheral vasodilation with cardioprotection [PubChem: Carvedilol]. These dual-acting drugs are particularly effective in chronic heart failure as they reduce the heart's workload while preventing the deleterious effects of chronic sympathetic overactivation [PubMed: 10450161]. Clinical use requires careful management to avoid safety concerns such as severe bradycardia, orthostatic hypotension, or exacerbation of reactive airway diseases [NIH: Beta-Blockers]. Monitoring of biomarkers like heart rate and blood pressure is essential to ensure therapeutic efficacy and patient safety during treatment [StatPearls: Beta Blockers].

Other names

AdrenoceptorsAdrenergic receptorsAlpha-1 and Beta adrenoceptorsBeta-adrenoceptors and Alpha-1-adrenoceptors

Competitive antagonism of alpha-1, beta-1, and beta-2 adrenergic receptors, leading to reduced systemic vascular resistance and decreased heart rate and contractility [PubChem: Carvedilol].